This excerpt taken from the TPTX 8-K filed Jun 8, 2006.


During the next 12 months, TorreyPines and Axonyx anticipate several key milestones related to their product candidates. Among these include the following:


TorreyPines’ lead compound, tezampanel, is expected to enter a Phase IIb clinical trial for the treatment of migraine


TorreyPines expects to file an Investigational New Drug (IND) application and then begin a Phase I trial for NGX426, the oral prodrug of tezampanel and the company’s follow-on compound for migraine and chronic pain


Axonyx will complete its ongoing Phase I trials with Posiphen™ for the treatment of AD progression


Data will become available from TorreyPines’ Phase I single dose study evaluating NGX267, the company’s lead muscarinic agonist, in healthy elderly volunteers – a population reflecting the age of the primary AD population






TorreyPines plans to initiate a multiple dose Phase I safety study with NGX267


Axonyx to begin a Phase I clinical trial with BNC, its highly selective butyrylcholinesterase inhibitor for the treatment of severe AD


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki